Related Experiment Videos
Moxalactam retinal toxicity
Abstract:
Moxalactam disodium is a new third-generation semisynthetic, broad-spectrum, cephalosporin-like antibiotic for parenteral administration. Topical, subconjunctival, and intravenous administration provide poor concentration in the vitreous. To determine its toxicity in intravitreal administration, we injected comparative doses directly into the vitreous cavity of 21 rabbits. With doses of 1.25 mg or less there was no toxic damage to the retina. With a dose of 2.5 mg, early degeneration of photoreceptors was seen after three months. With higher doses (5 and 10 mg) there were major histopathologic and electroretinographic changes. These results suggest the feasibility of employing moxalactam in the treatment of acute, severe, fulminant bacterial endophthalmitis.
Insights
Moxalactam disodium, a broad-spectrum antibiotic, showed no retinal toxicity at doses of 1.25 mg or less when injected intravitreally in rabbits. Higher doses caused retinal degeneration, suggesting potential use in treating severe bacterial endophthalmitis.
Area of Science:
- Ophthalmology
- Pharmacology
- Microbiology
Background:
- Moxalactam disodium is a third-generation cephalosporin-like antibiotic.
- Parenteral administration routes yield poor vitreous concentrations.
- Intravitreal administration requires toxicity assessment.
Purpose of the Study:
- To evaluate the toxicity of moxalactam disodium following direct intravitreal injection.
- To determine the safety threshold for intravitreal moxalactam disodium administration.
Main Methods:
- Intravitreal injections of varying moxalactam disodium doses (1.25 mg to 10 mg) were administered to 21 rabbits.
- Retinal toxicity was assessed through histopathological and electroretinographic examinations.
Main Results:
- Doses of 1.25 mg or less did not cause toxic retinal damage.
- A dose of 2.5 mg led to early photoreceptor degeneration after three months.
- Higher doses (5 mg and 10 mg) resulted in significant histopathologic and electroretinographic changes.
Conclusions:
- Intravitreal administration of moxalactam disodium is feasible at doses up to 1.25 mg without causing retinal toxicity.
- Moxalactam disodium may be a viable treatment option for acute, severe bacterial endophthalmitis.